现代治疗策略使90%妊娠类风湿关节炎患者达到低疾病活动度:PreCARA研究
PreCARA队列纳入309例有生育意愿或已妊娠的类风湿关节炎患者,采用改良达标治疗(T2T)策略并允许使用TNF抑制剂,与2002-2010年PARA历史队列比较。PreCARA队列平均疾病活动度低于PARA队列(p<0.001),低疾病活动度或缓解比例从孕前75.4%升至妊娠晚期90.4%,PARA队列分别为33.2%和47.3%。
要点
- 现代T2T策略下90.4%妊娠RA患者在妊娠晚期达到LDA或缓解。
- 孕期使用TNF抑制剂者占47.3%,平均疾病活动度低于历史队列。
- 孕前LDA或缓解比例75.4%,提示孕前达标管理的重要性。
核心结论
- 现代治疗策略(含T2T和TNF抑制剂)使妊娠RA患者达到LDA或缓解成为可实现的目标,妊娠晚期90.4%达标。
研究设计与样本
- PreCARA队列纳入309例有生育意愿或已妊娠的RA患者,按改良T2T策略治疗,与PARA历史队列(2002-2010年标准治疗)比较。
- 采用线性混合模型检验两队列疾病活动度随时间变化的差异。
主要发现
- PreCARA队列平均疾病活动度低于PARA参考队列(p<0.001)。
- PreCARA队列LDA或缓解比例从孕前75.4%升至妊娠晚期90.4%,PARA队列分别为33.2%和47.3%。
- PreCARA队列47.3%的患者在孕期任一时期使用TNF抑制剂,共188名儿童出生。
关键数值与推荐
- PreCARA队列妊娠晚期LDA或缓解比例为90.4%,PARA队列为47.3%。
- PreCARA队列孕前LDA或缓解比例为75.4%,PARA队列为33.2%。
临床怎么用
- 对有生育意愿或已妊娠的RA患者,可考虑采用改良T2T策略并使TNF抑制剂,以降低疾病活动度、提高孕期达标率。
局限性
- 与历史队列比较可能存在时代混杂,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with rheumatoid arthritis (RA), high disease activity impairs fertility outcomes and increases the risk of adverse pregnancy outcomes. The aim of this study was to determine the feasibility of a modern treatment approach, including treat-to-target (T2T) and the prescription of tumour necrosis factor (TNF) inhibitors, in patients with RA with a wish to conceive or who are pregnant. METHODS: Patients were derived from the Preconception Counseling in Active RA (PreCARA) cohort. Patients with a wish to conceive or who are pregnant were treated according to a modified T2T approach, in which the obvious restrictions of pregnancy were taken into account. Results of the PreCARA study were compared with results of the Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study, a historic reference cohort on RA during pregnancy. Patients in the PARA cohort were treated according to the standards of that time (2002-2010). Differences in disease activity over time between the two cohorts were tested using a linear mixed model. RESULTS: 309 patients with RA were included in the PreCARA study, 188 children were born. 47.3% of the patients used a TNF inhibitor at any time during pregnancy. Mean disease activity over time in the PreCARA cohort was lower than in the reference cohort (p<0.001). In the PreCARA cohort, 75.4% of the patients were in low disease activity (LDA) or remission before pregnancy increasing to 90.4% in the third trimester, whereas in the PARA cohort, these percentages were 33.2% and 47.3%, respectively. CONCLUSIONS: This first study on a modern treatment approach in pregnant patients with RA shows that LDA and remission are an attainable goal during pregnancy, with 90.4% of patients achieving this in the third trimester.
引用
- Smeele HT, Röder E, Wintjes HM, et al. Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study. Ann Rheum Dis. 2021. PMID: 33568387. doi:10.1136/annrheumdis-2020-219547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。